Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: GlobeNewswire
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (pAll secondary efficacy endpoints met (p1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours)Well-tolerated safety profile of deucrictibant confirmedEfficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with normal C1 inhibitor) and varying attack severities and locationsPharvaris to host a conference call and webcast today at 8:00 a.m. EST ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced RAPIDe-3 pivotal data confirming the potential of deucrictibant’s differentiate
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..MarketBeat
- Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Bank of America Corporation from $27.00 to $30.00. They now have a "neutral" rating on the stock.MarketBeat
- Pharvaris (PHVS) Is Up 5.9% After Phase 3 RAPIDe-3 Win - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Pharvaris (NASDAQ:PHVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
PHVS
Earnings
- 11/12/25 - Beat
PHVS
Sec Filings
- 12/4/25 - Form 144
- 12/3/25 - Form 144
- 12/3/25 - Form 144
- PHVS's page on the SEC website